Swiss stocks - Factors to watch on March 25
25/03/2015 07:08
ZURICH, March 25 (Reuters) - The Swiss blue-chip SMI .SSMI
was seen opening 0.2 percent lower on Wednesday at 9,277 points,
according to premarket indications by bank Julius Baer
JBPRE01 .
The following are some of the main factors expected to
affect Swiss stocks on Wednesday:
VONTOBEL VONN.S
The Swiss bank said it would acquire a 60 percent stake in
London-based TwentyFour Asset Management, which has around 4.4
billion pounds ($6.54 billion) in assets under management.
For more click on VONN.S
COMPANY STATEMENTS CPR-CH
* Newron Pharmaceuticals NWRN.S said shareholders
authorized it to allocate up to 1.3 million shares to raise
capital. NWRN.S
* Aryzta AG ARYN.VX announced an offering of up to 49
million ordinary shares in Origin Enterprises by way of an
accelerated book-building process to a limited number of
institutional investors. Aryzta holds 85.3 million Origin
shares, representing around 68.1 percent of the company's issued
share capital. ARN.VX
* Gategroup GATE.S released the invitation to its 2015
annual general meeting and recommended shareholders vote against
proposals of two hedge funds. GATE.S
* Lindt's LISN.S U.S. arm issued an allergy alert on
undeclared hazelnuts in chocolate covered raisin and chocolate
covered almond bags. LISN.S
* SHL Telemedicine SMDCY.PK said its board had unanimously
resolved to appoint Oren Most as the company's new non-executive
chairman of the board and had also resolved to initiate a
process of identifying a candidate for the position of the chief
executive. SMDCY.PK
* Nationale Suisse NATN.S said a Swiss court has declared
the shares not held by Helvetia HELN.S to be invalid. Based on
this judgment and the delisting decision of SIX Exchange
Regulation, all Nationale Suisse registered shares will be
delisted with effect from April 7, the company said. NATN.S
* Schindler Holding SCHN.S said the Swiss takeover board
had authorized higher daily volumes within the limits of its
ongoing repurchase programme of its registered shares. SCHN.S
* Cosmo Pharmaceuticals COPN.S said net profit for 2014
was 73.3 million euros, compared to 68.7 million euros in 2013.
COPN.S
* Cytos Biotechnology CYTN.S said Novartis NOVN.VX has
agreed to make a one-time payment of 4 million Swiss francs to
eliminate any further payment obligations under an agreement for
CAD106, which is under development by Novartis for the
prevention of Alzheimer's disease.
ECONOMY M-CH
The UBS Swiss consumption indicator rose to 1.19 points in
February from 1.11 points in January, the Swiss bank's
economists said on Wednesday.
(Reporting by Zurich newsroom)
((+41 58 306 7336)(zurich.newsroom@thomsonreuters.com))